EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked ...

Valitor Presents Preclinical Data Demonstrating Superior Durability with Six-month Treatment Protocol of VLTR-559 to Treat Wet AMD

VLTR-559 demonstrates sustained anti-VEGF activity and favorable safety at target clinical dosefor treatment of wetage-related macular ...
The Manila Times

MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in ...

MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II ...
Ophthalmology Times

QA102 data suggest signal in intermediate dry AMD, but insignificant drusen volume change

According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...